Phase 2Recruiting
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss (PRESERVE)
A Double-Blind, Randomized, Multi-Center, Dose-Ranging, Phase 2 Study of the Efficacy and Safety of ALV-100 Versus Placebo for Maintenance of Weight Loss in Patients Previously Treated With Incretin-Based Therapies
- Sponsor
- Alveus Therapeutics, Inc. (Industry)
- Enrolment
- 220 planned
- Conditions
- Overweight , Obesity; Adults
- Interventions
- ALV-100; Placebo
- Ages
- adults, older adults
- Registry
- NCT07837973
Full record on ClinicalTrials.gov
From the registry
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
Primary outcomes
- Dose response of ALV-100 as assessed by maintenance of weight loss
History
Primary completion expected
Last registry update
Registered
Started